Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07388277 · ClinicalTrials.gov registry record · Phase 1
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
A Phase 1 study, sponsored by Marcela V. Maus, M.D.,Ph.D..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07388277 is a Phase 1 study that is actively recruiting participants, run by Marcela V. Maus, M.D.,Ph.D.. The registered enrollment target is 12 participants.
The verdict
NCT07388277, a Phase 1 study, is actively recruiting participants, sponsored by Marcela V. Maus, M.D.,Ph.D..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Interventions
- DRUG Lymphodepletion Chemotherapy
- DRUG CC-97540
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-07-09 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07388277
The ClinicalTrials.gov registry entry for NCT07388277 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marcela V. Maus, M.D.,Ph.D., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lymphodepletion Chemotherapy is the first listed.
NCT07388277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07388277 about?
NCT07388277 is a clinical study titled "CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis". The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
What is the current status of trial NCT07388277?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-07-09. Estimated completion is 2029-12-31.
What interventions are being tested in trial NCT07388277?
The interventions under investigation include: Lymphodepletion Chemotherapy (DRUG), CC-97540 (DRUG).
Who is sponsoring clinical trial NCT07388277?
This trial is sponsored by Marcela V. Maus, M.D.,Ph.D., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.